AKT1 and leukemia: Preclinical investigations have shown that inhibitors directed against the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway can bolster the proliferative capacity, persistence, and anti-neoplastic potency of CAR-Ts in leukemia model systems [108].